Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE
Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO[see WARNINGS AND PRECAUTIONS, PatientCounseling Information].
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with theadministration of IGIV products inpredisposed patients. Renal dysfunction andacute renalfailure occur morecommonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose[see WARNINGS AND PRECAUTIONS].
For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients beforeadministration. Monitor for signs and symptoms of thrombosis and assess blood viscosity inpatients at risk for hyperviscosity[see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
YIMMUGO, immune globulin intravenous, human – dira, is a highly purified, sterile, non-pyrogenic, ready-to-use 10% liquid preparation of concentrated polyclonal human immune globulin G (IgG) antibodies for intravenous administration. The product is a clear to slightly opalescent liquid, which is colorless to pale yellow. The active ingredient is human IgG purified from human Source Plasma and processed using a combination of cold ethanol fractionation, caprylic acid precipitation, as well as anion and cation exchange chromatography. YIMMUGO contains 100 ± 10 mg/mL protein, of which not less than 96% is IgG. The distribution of IgG subclasses is similar to that of normal plasma. YIMMUGO is formulated in water for injection containing 0.27 to 0.33 mmol/mL glycine, 2 to 20 mcg/mL polysorbate 80, with pH 4.4 to 5.2 and osmolality ranges of 280 to 380 mOsmol/kg. YIMMUGO contains not more than 300 mcg/mL of IgA. YIMMUGO does not contain carbohydrate stabilizers (e.g., sucrose, maltose) or preservatives.
YIMMUGO is prepared from pooled plasma obtained from healthy volunteer donors. Each plasma donation used for the manufacture of YIMMUGO is collected from FDA-licensed facilities. Plasma donations must test negative for hepatitis B virus (HBV) surface antigen (HBsAg), antibodies to human immunodeficiency virus (HIV) strains 1 and 2 (anti-HIV-½), and antibodies to the hepatitis C virus (anti-HCV) as determined by enzyme immunoassay (EIA). In addition, samples from manufacturing pools must test non-reactive for HIV RNA, HCV RNA, HBV DNA and Hepatitis A Virus (HAV) RNA, by Nucleic Acid Amplification Testing (NAT). Parvovirus B19 (B19V) DNA is also tested by NAT and must not exceed 104 IU/mL in the manufacturing pool.
The manufacturing process of YIMMUGO employs several steps to remove/inactivate adventitious viruses to further increase the margins of safety. These steps include caprylic acid, low pH treatment, anion exchange chromatography (AEX) and nanofiltration. Virus clearance studies with a scaled-down process have been performed for these steps to determine their capacity to inactivate or remove both enveloped and non-enveloped viruses. The results are shown in Table 3.
Table 3: Virus Clearance Data (Log10) for YIMMUGO for enveloped (HIV, BVDV, PRV) and non-enveloped viruses (HAV, EMCV, B19V, PPV, HEV)
| Test Virus → ↓Step | HIV | BVDV | PRV | HAV | EMCV | B19V* | PPV | HEV* |
| Caprylic Acid Treatment | ≥ 5.64 | ≥ 5.97 | ≥ 6.21 | ≥ 4.39 | n.d. | 2.48 | 1.01 | ≥ 4.96 |
| Low pH Treatment | ≥ 6.63 | < 1 | n.d. | n.d. | n.d. | n.d. | < 1 | n.d. |
| Anion Exchange Chromatography | n.d. | 2.62 | n.d. | > 3.95 | n.d. | ≥ 5.86 | 3.21 | n.d. |
| Virus Filtration | ≥ 4.72 | ≥ 4.72 | n.d. | ≥ 4.37 | ≥ 4.93 | ≥ 4.33 | 6.12 | n.d. |
| Total Virus Clearance † | ≥ 16.99 | ≥ 13.31 | ≥ 6.21 | ≥ 12.71 | ≥ 4.93 | ≥ 12.67 | 10.34 | ≥ 4.96 |
| n.d. not determined. * Polymerase chain reaction (PCR) was used to quantify B19V and HEV genome counts (all other viruses were quantified by in-vitro infectivity assays, using mammalian cell lines). † Log10 reduction factors of 1 or smaller were not considered for calculation of total virus clearance. BVDV, bovine viral diarrhea virus, a model for hepatitis C virus; PRV, pseudorabies virus, a model for hepatitis B virus; EMCV, encephalomyocarditis virus, a model for hepatitis A virus; B19V, parvovirus B19; Â PPV, porcine parvovirus, a model for B19V; HEV, hepatitis E virus. |
||||||||
The manufacturing process was also investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered a model for CJD and its variant vCJD. Several of the production steps have been shown to decrease TSE infectivity of the experimental model agent. TSE reduction steps include caprylic acid treatment followed by depth filtration (in sequence, a total of ≥ 5.99 log10). These studies provide reasonable assurance that low levels of vCJD/CJD agent infectivity, if present in the starting material, would be removed.
YIMMUGO (immune globulin intravenous, human-dira), is a 10% immune globulin liquid, indicated for the treatment of primary humoral immunodeficiency (PI) including but not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID) in patients 2 years of age and older.
For intravenous use only.
Table 1: Recommended Dosage and Administration
| Dose | Infusion Number | Initial Infusion Rate | Maintenance Infusion Rate (if tolerated) |
| 300-800 mg/kg (3-8 mL/kg) every 3-4 weeks | For the 1st infusion | 0.5 mg/kg/min (0.005 mL/kg/min) for 30 minutes | Gradually increase every 30 minutes up to 3.0 mg/kg/min (0.03 mL/kg/min). |
| 300-800 mg/kg (3-8 mL/kg) every 3-4 weeks | From the 2nd infusion | 0.5 mg/kg/min (0.005 mL/kg/min) for 30 minutes | Gradually increase up to 13 mg/kg/min (0.13 mL/kg/min). |
The dosage may be adjusted over time to achieve the desired trough levels and clinical response.
Administer YIMMUGO at room temperature or body temperature by the intravenous route. Do not mix with any intravenously administered medications. For rate of infusion, refer to Table 1. Monitor patient vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.
Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer YIMMUGO at the minimum infusion rate practicable, and consider discontinuation of administration if renal function deteriorates [see BOXED WARNING, WARNINGS AND PRECAUTIONS].
Hydrate the patient adequately prior to the initiation of infusion.
YIMMUGO is a solution containing 10% IgG (100 mg/mL): 5 g in 50 mL, 10 g in 100 mL, 20 g in 200 mL.
YIMMUGO is supplied in 5, 10 and 20 gram single-dose vials.
| Package NDC | Container NDC | Size | Gram Protein |
| 83372-605-01 | 83372-605-02 | 50 mL | 5 |
| 83372-605-11 | 83372-605-12 | 100 mL | 10 |
| 83372-605-21 | 83372-605-22 | 200 mL | 20 |
Manufactured by: Biotest AG, 63303 Dreieich, Germany. Revised: Jun 2024
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In an open-label, prospective, multicenter, multinational trial, the efficacy, safety, and pharmacokinetic properties of YIMMUGO as replacement therapy in patients with PI were investigated in 67 patients (including 12 children and 6 adolescents).5,6 Patients received a dose between 200 mg to 800 mg per kg body weight (bw) every 3 or 4 weeks, for a treatment period of approximately 12 months. The initial dose and dosage interval was consistent with the patient’s prestudy IGIV treatment [see Clinical Studies].
There were two serious adverse events (SAEs) related to YIMMUGO, occurring in two patients: anaphylactic reaction, and severe neutropenia. Both SAEs led to discontinuation of YIMMUGO. One patient also had mild hemolysis and positive Coomb’s test.
Adverse reactions (AR) occurring in ≥5% of patients are presented in Table 2.
Table 2: Adverse Reactions * in ≥ 5% of Patients
| Adverse Reaction MedDRA - Preferred Term |
Number (%) of Patients with AR N = 67 |
Number (%) of Infusions Ninf = 923 |
| ≥1 Adverse reaction | 39 (58) | 93 (10) |
| Headache | 13 (19) | 22 (2) |
| Upper respiratory tract infections | 8 (12) | 8 (<1) |
| Fatigue | 5 (8) | 8 (<1) |
| Nausea | 4 (6) | 5 (<1) |
| Increased blood pressure | 4 (6) | 4 (<1) |
| * Adverse reactions were identified as all AEs that were temporally associated with an infusion (occurred during infusion or within 72 h after the end of an infusion) or that were assessed as related. | ||
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified and reported during the post-approval use of IGIV products:
Clinical studies have not evaluated mixture of YIMMUGO (immune globulin intravenous, human-dira) with other intravenous drugs and solutions. Administer YIMMUGO separately from other drugs or medications which the patient may be receiving. Do not mix YIMMUGO with other IGIVs products.
Immunoglobulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, and varicella because the continued presence of high levels of passively acquired antibody may interfere with an active antibody response.7 Inform the immunizing physician of recent therapy with YIMMUGO so that appropriate measures may be taken [see Patient Counseling Information].
Various passively transferred antibodies in immunoglobulin preparation may lead to misinterpretation of the results of serological testing.
Avoid concomitant use of loop diuretics. Concomitant use of loop diuretics with IGIV may additionally contribute to an increased blood viscosity and subsequently increase the risk of thromboembolic events.
REFERENCES
5. Kriván G, Borte M, Harris JB, Lumry WR, Aigner S, Lentze S, et al. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease. Vox Sang 2022;117:1153-62.
6. Kriván G, Borte M, Soler-Palacin P, Church JA, Csurke I, Harris JB, et al. BT595, a 10% human normal immunoglobulin, for replacement therapy of primary immunodeficiency disease: results of a subcohort analysis in children. J Clin Immunol 2023;43:557-67.
7. Siber GA, Werner BG, Halsey NA, Reid R, Almeido-Hll J, Garrett SC, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993;122:204-11.
Included as part of the PRECAUTIONS section.
Severe hypersensitivity reactions, including anaphylaxis, have been reported after YIMMUGO administration. [see CONTRAINDICATIONS]. In case of hypersensitivity, discontinue YIMMUGO infusion immediately and institute appropriate treatment. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions.
YIMMUGO contains less than or equal to 300 micrograms per milliliter of IgA [see DESCRIPTION]. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. YIMMUGO is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity reaction [see CONTRAINDICATIONS].
Hemolysis has been reported after YIMMUGO administration. IGIV products, including YIMMUGO, may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and hemolysis.1 Delayed hemolytic anemia can develop subsequent to IGIV treatment due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis.The following risk factors may be associated with the development of hemolysis following IGIV administration: high doses (e.g. ≥2 g/kg given either as a single administration or divided over several days), and non-O blood group. Other individual patient factors, such as underlying inflammatory state (as may be reflected by elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV, but their role is uncertain.
Monitor patients for clinical signs and symptoms of hemolysis [see Patient Counseling Information]. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit are observed after YIMMUGO infusion, perform confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with anemia after receiving IGIV, perform cross-matching to avoid exacerbating ongoing hemolysis.
Thrombosis may occur following treatment with immune globulin products,2,3 including YIMMUGO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including patients with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see BOXED WARNING, DOSAGE AND ADMINISTRATION, Patient Counseling Information].
Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering YIMMUGO. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, hypovolemia, overweight, use of concomitant nephrotoxic drugs, or age of >65 years), administer YIMMUGO at the minimum infusion rate practicable [see BOXED WARNING and DOSAGE AND ADMINISTRATION].
Conduct periodic monitoring of renal function and urine output in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of YIMMUGO and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing YIMMUGO [see Patient Counseling Information].
Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV treatment, including YIMMUGO. It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thromboembolic events.
Aseptic meningitis syndrome (AMS) may occur infrequently in patients following IGIV treatments, including YIMMUGO. AMS usually begins within several hours to 2 days following IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.4 AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting [see Patient Counseling Information]. Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting signs and symptoms of AMS, including CSF studies, to rule out other causes of meningitis.
AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.
Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)] may occur in patients following IGIV treatment,4 including YIMMUGO. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function and fever. Symptoms typically appear within 1 to 6 hours following treatment.
Monitor patients for pulmonary adverse reactions. If TRALI is suspected immediately stop IGIV and perform appropriate tests for the presence of anti-neutrophil antibodies and anti-human leukocyte antigen (HLA) antibodies in both the product and the patient’s serum [see Patient Counseling Information].
TRALI is a potentially life-threatening condition requiring immediate intensive-care-unit management. TRALI may be managed using oxygen therapy with adequate ventilatory support.
Because YIMMUGO is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. The risk of infectious agent transmission has been reduced by screening plasma donors and by including virus inactivation as well as virus and prion removal steps in the manufacturing process of YIMMUGO.
All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Grifols at 1-800-520-2807. Discuss the risks and benefits of YIMMUGO use with patient before prescribing or administering this product.[see Patient Counseling Information].
After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation.
Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.
No animal studies were conducted to evaluate the carcinogenic or mutagenic effects of YIMMUGO or its effects on fertility.
No human data are available to indicate the presence or absence of drug-associated risk. Animal reproduction studies have not been conducted with YIMMUGO. It is not known whether YIMMUGO can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively. YIMMUGO should be given to pregnant women only if clearly needed.
No human data are available to indicate the presence or absence of drug-associated risk. Immune globulins are excreted into human milk. The developmental and health benefits of breast feeding should be considered along with the mother’s clinical need for YIMMUGO and any potential adverse effects on the breast-fed infant from YIMMUGO or from the underlying maternal condition.
YIMMUGO was evaluated in 18 pediatric patients (12 children age 2 to less than 12 years and 6 adolescents age 12 – 16 years) with PI. Dose requirements did not differ between children and adults. Safety and effectiveness has not been studied in pediatric patients with PI who are under the age of 2 years [see Clinical Studies].
Clinical studies of YIMMUGO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients . Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see BOXED WARNING, WARNINGS AND PRECAUTIONS]. Do not exceed recommended doses, and administer YIMMUGO at the minimum infusion rate practicable.
REFERENCES
1. Bellac, CL, Hottiger T, Jutzi MP, Bögli-Stuber K, Sänger M, Hanschmann K-M, et al. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion 2015;55 Suppl 2:S13-22.
2. Dalakas, MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
3. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-4.
4. Guo, Y, Tian X, Wang X,Xiao Z.Adverse effects of immunoglobulin therapy. Front Immunol 2018;9:1299.
Overdose may lead to fluid overload and hyperviscosity. Patients at risk of complications of fluid overload and hyperviscosity include infants, elderly patients and those with cardiac or renal impairment.
YIMMUGO provides a broad spectrum of opsonizing and neutralizing immune globulin G (IgG) antibodies against a wide variety of pathogens and their toxins, which helps to avoid recurrent serious opportunistic infections. The mechanism of action has not been fully elucidated but may include immunomodulatory effects.
YIMMUGO contains mainly IgG with a broad spectrum of antibodies against various infectious agents, reflecting the IgG activity found in the donor population. YIMMUGO which is prepared from pooled plasma from not less than 1,000 donors, has an IgG subclass distribution similar to that of native human plasma. Adequate doses of IGIV can restore an abnormally low IgG level to the normal range. Standard pharmacodynamics studies were not performed.
The pharmacokinetic parameters for YIMMUGO were determined in an open-label, prospective, multicenter, multinational clinical trial in 57 patients with PI [see Clinical Studies]. IgG levels for determination of PK parameters were measured after the 7th (3-week schedule, n = 10) or 5th infusion (4-week schedule, n = 47) in 57 patients (6 to <76 years of age). Patients for whom PK data was available received doses of YIMMUGO between 280 mg/kg to 800 mg/kg. The mean half-life of YIMMUGO for adults was 24.8–29.9 days depending on the treatment schedule (see Table 4). PK parameters did not indicate any clinically relevant differences between the 3-week and 4-week schedule.
Table 4: Pharmacokinetic Parameters of YIMMUGO at Steady State
| a) PK Parameters: 3 Week Schedule - Mean (SD) | |||
| Parameter | 6-<12 Years | 12-<17 Years | 17-<76 Years |
| N* | 2 | 1 | 7 |
| Cmax (mg/mL) | 19.6(3.9) | 34 8 | 32.3(6.3) |
| Ctrough ( mg/mL) | 8 1(0.2) | 13 | 10.4(2.4) |
| AUCtau (day x g/L) | 238.7(5.9) | 477 | 398.4(99) |
| CLss (mL/day/kg) | 2(0.3) | 1.2 | 1.4(0.3) |
| Vss (mL/kg) | 69.4(23) | 11 27 | 53.5(15.7) |
| Half-life (days) | 29.5,n=1 | 15.5 | 24.8(5.1),n=5 |
| b) PK Parameters: 4 Week Schedule - Mean (SD) | |||
| Parameter | 6-<12 Years | 12-<17 Years | 17-<76 Years |
| N* | 3 | 5 | 39 |
| Cmax (mg/mL) | 24.7 (1.2), n=2 | 22.2 (2.3), n=4 | 27.1 (6.3) |
| Ctrough (mg/mL) | 7.1 (1.2), n=3 | 9.1 (1.7), n=5 | 8.1 (2.5) |
| AUCtau (day x g/L) | 392.1(19.7),n=2 | 415.1(94.9),n=4 | 397 (103.6), n=36 |
| CLss (mL/day/kg) | 1(0.1),n=2 | 0.9(0.3),n=4 | 1.3(0.5),n=36 |
| Vss (mL/kg) | 74.6(7.2),n=2 | 56.5(12.8),n=4 | 61.8(39.1),n=35 |
| Half-life (days) | 57.5, n=1 | 31.7 (3), n=2 | 29.9(12.4), n=22 |
| * Divergent number of subjects for individual PK parameters are indicated behind values. Abbreviations: AUCtau = area under the concentration-time curve calculated from start to end of the dosing interval; CLss = clearance at steady state; Cmax = maximum serum concentration; Ctrough = trough concentration at steady state; n = number of subjects with data; SD = standard deviation; Vss = volume of distribution at steady state |
|||
Although no systematic study was conducted to evaluate the effect of sex on the pharmacokinetics of YIMMUGO, subgroup analysis between males (n= 37) and females (n = 30) revealed no clinically relevant differences in exposure and IgG trough levels.
A single dose toxicology study in male and female Sprague Dawley rats was conducted. Study endpoints included clinical and hematological evaluations, post-mortem analyses, and sensory-motor activity evaluations on days 1 and 15 post-dosing. Under the conditions of this study, the single intravenous infusion administration of YIMMUGO at a dose level of 2 g/kg body weight given at a rate of 20 mL/kg for 40 minutes was not associated with any adverse findings.
Trial 991(NCT02810444): The safety, effectiveness and pharmacokinetics of YIMMUGO as replacement therapy in patients with PI were investigated in an open-label, prospective, multicenter, multinational trial. The study planned to enroll patients 2 to 75 years of age with PI who had established IGIV therapy for at least 3 months with a constant dose, and at least one IgG trough level of ≥5g/L during the previous 3 months. The patients were to receive YIMMUGO at doses between 0.2 to 0.8 g per kg body weight (bw) at either 3-week (Q3W) or 4-week (Q4W) intervals for a period of 12 months. The initial dose and dosage interval had to be consistent with the subject’s prestudy IGIV treatment and doses were to be adjusted for changes in weight or as medically indicated.
The primary efficacy outcome measure was the rate of serious bacterial infections (SBI), defined as bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, visceral abscesses, or bacterial meningitis over a period of 12 months. The predefined success criteria was demonstration of rate of less than one acute SBI per patient per year. Additional efficacy outcome measures included occurrence of any infection, time to resolution of infections, use of antibiotics, the number of days missed from work/school, and hospitalizations.
The trial enrolled 67 patients with a mean age of 35 years (range 2 to 74 years). There were 18 pediatric patients (including 12 children and 6 adolescents), and 5 patients ≥65 years of age. The study population was mainly white (n=66; 98.5%) and males represented 55% (n=37). The most common underlying cause of PI was CVID (n=53; 79%). Other etiologies included XLA (n=10; 15%), congenital agammaglobulinaemia (n=2; 3%), congenital hypogammaglobulinaemia (n=1; 1.5%), and specific antibody defect (n=1; 1.5%).
Patients received a dose ranging from 200 mg to 833 mg per kg body weight (bw) every 3 (n=12) or 4 weeks (n=55), for a treatment period of approximately 12 months. Infusions were initiated at a rate of 0.5 mg/kg/min (0.005 mL/kg/min) for the first 30 minutes, and, if tolerated, could be increased to a maximum tolerated rate not exceeding 13 mg/kg/min (0.13mL/kg/min). During the study 10 patients required a dose adjustment (increase) due to low IgG levels (including 7 patients who had trough levels <5 g/L). Additionally, 2 patients required dose adjustment (increase) due to infections, and 1 patient required a dose reduction due to an adverse reaction (worsening of fatigue).
The study demonstrated that treatment with YIMMUGO resulted in less than one SBI per person-year. A total of five acute SBIs occurred among study participants. All five acute SBIs were bacterial pneumonia. A summary of efficacy outcomes is shown in Table 5.
Table 5: Summary of Efficacy Results in Trial 991
| Category | Results |
| Number of Patients | 67 patients with 67.6 years on study |
| Infections | |
| Annualized rate of acute SBIs | 0.07 acute SBIs/person-year (99% CI 0.21) |
| Annualized rate of other infections | 2.7 infections/person-year |
| Time to resolution of infection* | 7 (1, 172) days† |
| Antibiotics | |
| Number of patients with therapeutic antibiotic use | 35 subjects (52.2%) |
| Number of days on therapeutic antibiotics* | 9.5 (3, 35) days |
| Time lost from work/school | |
| Number of patients who lost ≥1 day due to infection | 26 subjects (38.8%) |
| Number of days lost from work/school due to infection* | 6 (1, 85) days |
| Hospitalizations due to infection | |
| Number of patients with hospitalizations due to infection | 3 subjects (4.5%) |
| Number of days hospitalized* | 2 (2, 20) days |
| Annualized rate of hospitalization due to infection | 0.36 days/person-year |
| *Number of days presented in median (min, max) among patients with events of a duration of ≥1 day; maximum duration was used if there were multiple events. †Two patients had unresolved infections at the last follow-up visit. |
|
Inform patients of the early signs of hypersensitivity reactions to YIMMUGO (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis), and advise them to notify their physician if they experience any of these symptoms [see WARNINGS AND PRECAUTIONS].
Instruct patients taking YIMMUGO to immediately report symptoms of:
Inform Patients That YIMMUGO
